IPCA Laboratories Limited — Others, 29-05-2025: Amendment to AOA/MOA

Ipca Laboratories has announced a board meeting in which it approved the financial results for the quarter and half-year ended March 31, 2025. The Board proposed a final dividend of Rs. 2/- per share (200%). Standalone net total income rose 8% to Rs. 6,749.21 Cr, while consolidated net total income increased 15% to Rs. 9,032.39 Cr. Standalone net profit before exceptional items grew 40% to Rs. 932.30 Cr, and consolidated net profit before exceptional items rose 56% to Rs. 992.58 Cr. Exceptional charges include impairment of Rs. 173 Cr on a US subsidiary and Rs. 108.54 Cr on an associate. The company plans to expand into green energy generation but will keep operations focused on pharmaceuticals, with consistent domestic and export growth in formulations and APIs. Audit reports were clean.